SLC5A2 and chronic kidney disease: Pooled analysis showed that significant changes of UACR in patients with T2DM and CKD after using SGLT2 inhibitors compared with placebo or other anti-diabetic medications (MD −24.27 mg/g, 95% CI −44.46 to −4.09, P = .02, shown in Fig. 8)